ArticleFrontiers in nutrition2025
Processed silkworm powder (Hongjam) ameliorates metabolic dysfunction-associated steatotic liver disease via GPR35/PKA and SIRT1/AMPK pathways.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic metabolic disorder linked to obesity, insulin resistance, and type 2 diabetes. This study aimed to investigate the preventive effects of Hongjam, a processed silkworm powder, in a high-fat diet-induced MASLD mouse model and to explore its underlying mechanisms. Methods: C57BL/6J mice were fed a high-fat diet with or without Hongjam supplementation. Serum lipid and glucose levels, hepatic lipid accumulation, liver injury markers, and inflammatory responses were evaluated. Mechanistic analyses focused on SIRT1/AMPK signaling, lipogenic and fatty acid oxidation gene expression, STAT3 phosphorylation, cytokine production, and GPR35/PKA-mediated gluconeogenesis. To identify bioactive components, a silk-derived fibroin peptide was synthesized and tested in palmitate-treated HepG2 cells. Results: Hongjam supplementation improved serum triglyceride, cholesterol, and glucose levels, reduced hepatic lipid accumulation, and lowered liver injury markers. These beneficial effects were associated with activation of the SIRT1/AMPK pathway, suppression of lipogenesis, and enhancement of fatty acid oxidation. Hongjam also attenuated hepatic inflammation by inhibiting STAT3 phosphorylation and reducing pro-inflammatory cytokines, while restoring gluconeogenic capacity through GPR35/PKA signaling. The fibroin peptide suppressed SREBP1 expression, reduced lipid accumulation, and reactivated SIRT1/AMPK and GPR35/PKA/CREB pathways in HepG2 cells. Discussion: These findings suggest that Hongjam and its fibroin-derived peptide exert protective metabolic effects by modulating lipid metabolism, inflammation, and glucose homeostasis. Together, they highlight the potential of Hongjam as a functional food ingredient for the prevention of MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.